https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39133 Wed 13 Mar 2024 14:14:30 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24220 A and −174 G>C) correlate with MS susceptibility, but with varying results. In the present study, we analyzed these polymorphisms, together with an additional polymorphism (−572 G>C) in 279 healthy controls and 509 patients with MS. We found no significant differences between MS patients and healthy controls for the different −597 or −174 IL6 promoter alleles or genotypes. There was a slight reduction in the percentage of individuals with MS who carried a C allele at position −572, although this was not significant after correction for multiple comparisons. Interestingly, however, the −572 C allele showed a significant correlation with the MS severity score, suggesting a possible role in disease progression.]]> Wed 11 Apr 2018 15:18:27 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15137 Wed 11 Apr 2018 14:14:06 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27387 14.3 years. After adjusting for confounders, diabetic subjects were 49% (cause-specific hazard ratio (_cHR) = 1.49, 95% CI: 1.37, 1.62) more likely to develop kidney failure than non-diabetic subjects. Albuminuria categories A3 and A2 were, respectively, 3.40 (95% CI: 3.07, 3.76) and 1.71 (95% CI: 1.53, 1.92) higher risk of kidney failure when compared to A1. For each albumin category, death rate increased as albuminuria increased particularly in diabetic subjects, which was approximately 2 times higher in A3 compared to A1. Considering GFR category, it gradually increased from G1 to G4 and sharply increased from G4 to G5 in both non-diabetic and diabetic subjects. This study has quantified CKD progression in an Asian population within ordinary practice. Diabetic subjects progress through GFR and albuminuria categories and reach kidney failure about twice as rapidly as non-diabetic subjects.]]> Wed 11 Apr 2018 10:07:38 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32656 Thu 05 Jul 2018 10:55:14 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21004 74 years: HR=2.73, 95% CI: 2.55-2.93), and those living in inner regional (HR=1.11, 95% CI: 1.04-1.18) or rural areas (HR=1.24, 95% CI: 1.14-1.36) or more disadvantaged areas (middle tertile: HR=1.09, 95% CI: 1.02-1.16; most disadvantaged: HR=1.12, 95% CI: 1.04-1.19). The risk of developing metastatic disease decreased over calendar time (adjusted HR=0.98, 95% CI: 0.97-0.99 per year). Conclusions: After a median follow-up of 6.8 years more than 1 in 5 men diagnosed with non-metastatic prostate cancer developed distant metastases. This estimate of the overall risk of developing metastatic disease in the population, and the geographical disparities identified, can inform the planning of required cancer services.]]> Sat 24 Mar 2018 07:50:38 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28324 Sat 24 Mar 2018 07:25:14 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51774 Mon 18 Sep 2023 14:29:20 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42619 Mon 04 Sep 2023 13:58:46 AEST ]]>